The European Society for Medical Oncology (ESMO) is Europe’s leading professional organization for medical oncology education and information. With over 13,000 members representing oncology professionals from more than 130 countries, they aim to support their members in this complex and ever-evolving medical environment. With European roots and a global reach, they welcome oncology professionals from around the world.
This ESMO Annual Congress aims to bring together clinicians, researchers, patient advocates, journalists, and the pharmaceutical industry from around the globe to learn about the latest advances in oncology and translate such progress into better cancer patient care. The SMO 018 Annual ongress took place in October this year in Munich, Germany.
The program of the ESMO 2018 Congress as eveloped by a committee composed of more than 300 international xperts under the leadership of Professor Solange Peters, head of medical oncology at the Centre ospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland. “I feel honoured to have been selected to lead the Scientific Committee of the ESMO 2018 Congress, and for being the second ever female Scientific Committee Chair, after [Professor] Martine Piccart in 2012,” she said in a press release.
Journal of Clinical Pathways was at the Congress in Germany to bring readers onsite coverage. Additional coverage of this meeting is available from the Oncology Learning Network here.
Novel PI3K Inhibitor Improves Survival for Patients with PIK3CA-Mutated Breast Cancer
The alpha-specific phosphatidylinositol-3-kinase inhibitor alpelisib significantly improved progression-free survival in patients with HR-positive, HER2-negative advanced breast cancer.
Local Radiotherapy Improves Survival in Patients With Oligometastatic Prostate Cancer
Radiotherapy to the prostate can improve survival in patients with newly-diagnosed metastatic prostate cancer who have a low metastatic disease burden, though not in those with a higher burden of disease.
Results from the phase 3 SOLO-1 trial show that 2-year maintenance therapy with PARP inhibitor olaparib led to a substantial, unprecedented improvement in progression-free survival in newly diagnosed patients with advanced ovarian cancer and a mutation in either of the BRCA1 and BRCA2 genes.
